Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126779841 | 12677984 | 1 | I | 20160721 | 20160816 | 20160823 | 20160823 | EXP | SE-MPA-2016-004511 | SE-PFIZER INC-2016389871 | PFIZER | 69.00 | YR | M | Y | 0.00000 | 20160823 | MD | SE | SE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126779841 | 12677984 | 1 | PS | Dalacin | CLINDAMYCINCLINDAMYCIN PHOSPHATE | 1 | UNK | Y | 50162 | CAPSULE, HARD | |||||||||
| 126779841 | 12677984 | 2 | SS | ENALAPRIL | ENALAPRIL | 1 | UNK | Y | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126779841 | 12677984 | 1 | Device related infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126779841 | 12677984 | OT |
| 126779841 | 12677984 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126779841 | 12677984 | Angioedema |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126779841 | 12677984 | 1 | 201607 | 0 | ||
| 126779841 | 12677984 | 2 | 20160721 | 0 |